• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

As U.S. Treasury intervened in the bond market, the Netherlands rushed 86 tons of gold out of America because of ‘geopolitical unrest’

2

He failed the military pilot eye test—so he built a $1 million-a-day traffic company and bought flying lessons. Now he’s Top Gun’s stunt pilot 

3

Despite being a multimillionaire, Suze Orman still cooks at home whenever possible—and says eating out is one of the biggest wastes of money

1

As U.S. Treasury intervened in the bond market, the Netherlands rushed 86 tons of gold out of America because of ‘geopolitical unrest’

2

He failed the military pilot eye test—so he built a $1 million-a-day traffic company and bought flying lessons. Now he’s Top Gun’s stunt pilot 

3

Despite being a multimillionaire, Suze Orman still cooks at home whenever possible—and says eating out is one of the biggest wastes of money
HealthBrainstorm Health

Brainstorm Health: Fentanyl Overdoses, J&J Clinical Win

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
December 12, 2018, 7:02 PM ET
Google source logo
Add Fortune on Google for similar content.

Happy hump day, readers.

It’s a busy week, but I wanted to highlight a piece from my colleague Erin Corbett on the latest, disconcerting data regarding the opioid addiction epidemic.

“According to the [Centers for Disease Control’s] National Center for Health Statistics, drug overdoses involving fentanyl increased by 113% each year between 2013 and 2016. The drug was involved in nearly 29% of all reported overdose deaths in 2016, a huge jump from just 4% five years earlier. At that point, oxycodone was the most common drug in overdoses, at 13%,” Erin writes.

Read on for the day’s news.

Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

INDICATIONS

J&J claims a head-to-head win in a lucrative space. Johnson & Johnson is ramping up its rivalry with Novartis in one of the most lucrative spaces in pharmaceuticals: dermatology and immunology. The firm is touting its psoriasis treatment Tremfya's efficacy against Novartis' rival Cosentyx. The stakes are high: This is a more than $20 billion market. (Reuters)

THE BIG PICTURE

Kaiser mental health strike leads to repercussions. A dispute between mental health workers and Kaiser management has led to the cancellation of certain non-urgent surgeries, according to CBS. Nearly 4,000 workers represented by the National Union of Healthcare Workers will reportedly strike through Friday in a dispute over staffing levels and pay. (CBS News)

REQUIRED READING

More Than 60% of Americans Didn't Get a Pay Raise Last Year, by Don Reisinger

Commentary: Twitter Has Become the Modern Day Colosseum, by Michael Fontaine

How Europe's Young Tech Industry Can Avoid Silicon Valley's Diversity Failure, by Grace Donnelly

Sesame Street Is Introducing Its First Homeless Puppet, by Emily Price

Produced by Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

Find past coverage. Sign up for other Fortune newsletters.
About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Google source logo
Add Fortune on Google for similar content.

Latest in Health


Most Popular

Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    Latest in Health


    Most Popular

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.